
WCLC 2018

Read the full Report (pdf)
IASLC World Conference on Lung Cancer 23-26 September 2018 Toronto, Canada
Featured articles


Interview with the IASCL President, Dr. Giorgio Scagliotti
CONTENTS
Online First
Presidential Symposium ā Top 5 abstracts
Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer

Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer

Benefits of chest CT screening

New standard of care in extensive-stage small-cell lung cancer
No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype
New Aspects of Immunotherapy

Next generation immunotherapy in non-small-cell lung cancer
Combination therapies: Where are we in 2018?

Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer
New Aspects of Targeted Therapy

PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib

Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC

Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative
Mesothelioma

Unmet needs in surgical management of malignant pleural mesothelioma
Angiogenic and stromal biomarkers in malignant mesothelioma
Advanced Non-small Cell Lung Cancer

Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer
Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer
Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer
Novel Therapies in ROS1 and EGFR
